Literature DB >> 29468306

Paratesticular alveolar rhabdomyosarcomas do not harbor typical translocations: a distinct entity with favorable prognosis?

Tobias M Dantonello1,2, Christian Vokuhl3, Monika Scheer4, Monika Sparber-Sauer4, Sabine Stegmaier4, Guido Seitz5, Heike Scheithauer6, Jörg Faber7, Iris Veit-Friedrich4, Peter Kaatsch8, Stefan S Bielack4,9, Thomas Klingebiel10, Ewa Koscielniak4,11.   

Abstract

The alveolar subtype of rhabdomyosarcoma (RMA) is a strong risk factor. Cases of RMA located in paratesticular sites have however been reported to have similar outcomes to those of embryonal rhabdomyosarcoma (RME). We wanted to re-evaluate the impact of subtype in paratesticular rhabdomyosarcoma (PT-RMS). Patients from a population-based cohort diagnosed with paratesticular RMA in 1990-2013 were analyzed. All tumor samples were re-reviewed using conventional morphology, immunohistochemistry, and molecular testing. Seven patients were eligible. Four tumors showed focal areas morphologically compatible with RMA (mixed RMA/RME). One case was undifferentiated, with a solid round-cell morphology which had to be reclassified as poorly differentiated RME. Two cases had a "microalveolar" morphology which is today regarded as sclerosing RME. No tumor showed the characteristic gene fusion of RMA. Five children had localized disease, one bone metastases, and another lymph-node involvement. All primaries were grossly resected. One locoregional relapse occurred. At a median follow-up of 7 years, all patients were alive disease-free. PT-RMS can show a focal alveolar histology combined with typical features of RME. In current morphological classifications, all rhabdomyosarcomas qualify for the alveolar subtype if typical features of RMA are realized at least focally. Rhabdomyosarcomas consisting of pure RMA morphology were however not found in our patients with PT-RMS. The mixed RMA/RMEs identified in our population-based study did not show a translocation typical for RMA and had a good prognosis. Further prospective studies need to evaluate if mixed RMA/RMEs have a similar favorable outcome in non-paratesticular sites as well.

Entities:  

Keywords:  Alveolar subtype; Paratesticular; Pediatric oncology; Rhabdomyosarcoma

Mesh:

Year:  2018        PMID: 29468306     DOI: 10.1007/s00428-018-2311-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  37 in total

1.  N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features.

Authors:  Y Hachitanda; S Toyoshima; K Akazawa; M Tsuneyoshi
Journal:  Mod Pathol       Date:  1998-12       Impact factor: 7.842

2.  Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma.

Authors:  Tobias M Dantonello; Monika Stark; Beate Timmermann; Jörg Fuchs; Barbara Selle; Christin Linderkamp; Rupert Handgretinger; Rudolf Hagen; Simone Feuchtgruber; Stefanie Kube; Daniel Kosztyla; Bernarda Kazanowska; Ruth Ladenstein; Felix Niggli; Gustaf Ljungman; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak
Journal:  Pediatr Blood Cancer       Date:  2014-09-27       Impact factor: 3.167

3.  Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86.

Authors:  E Koscielniak; D Harms; G Henze; H Jürgens; H Gadner; M Herbst; T Klingebiel; B F Schmidt; M Morgan; R Knietig; J Treuner
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

4.  PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.

Authors:  Edoardo Missiaglia; Dan Williamson; Julia Chisholm; Pratyaksha Wirapati; Gaëlle Pierron; Fabien Petel; Jean-Paul Concordet; Khin Thway; Odile Oberlin; Kathy Pritchard-Jones; Olivier Delattre; Mauro Delorenzi; Janet Shipley
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

5.  Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.

Authors:  Richard J Stewart; Hélène Martelli; Odile Oberlin; Annie Rey; Nathalie Bouvet; Richard D Spicer; Jan Godzinski; Michael C G Stevens
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

6.  Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.

Authors:  Thomas Klingebiel; Joachim Boos; Florian Beske; Erika Hallmen; Christoph Int-Veen; Tobias Dantonello; Joern Treuner; Helmut Gadner; Ildiko Marky; Bernarda Kazanowska; Ewa Koscielniak
Journal:  Pediatr Blood Cancer       Date:  2008-04       Impact factor: 3.167

7.  Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study.

Authors:  W A Newton; E A Gehan; B L Webber; H B Marsden; A J van Unnik; A B Hamoudi; M G Tsokos; H Shimada; D Harms; D Schmidt
Journal:  Cancer       Date:  1995-09-15       Impact factor: 6.860

8.  Is alveolar histotype a prognostic factor in paratesticular rhabdomyosarcoma? The experience of Italian and German Soft Tissue Sarcoma Cooperative Group.

Authors:  Andrea Ferrari; G Bisogno; M Casanova; I B Brecht; R Alaggio; G Cecchetto; M Provenzi; E Koscielniak; J Treuner; M Carli
Journal:  Pediatr Blood Cancer       Date:  2004-02       Impact factor: 3.167

Review 9.  Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.

Authors:  C Rossig; H Juergens; M Schrappe; A Moericke; G Henze; A von Stackelberg; D Reinhardt; B Burkhardt; W Woessmann; M Zimmermann; H Gadner; G Mann; G Schellong; C Mauz-Koerholz; U Dirksen; S Bielack; F Berthold; N Graf; S Rutkowski; G Calaminus; P Kaatsch; U Creutzig
Journal:  Pediatr Blood Cancer       Date:  2013-06-05       Impact factor: 3.167

Review 10.  The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.

Authors:  Abby R Rosenberg; Stephen X Skapek; Douglas S Hawkins
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-07       Impact factor: 4.254

View more
  1 in total

1.  Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.

Authors:  Timothy N Rogers; Guido Seitz; Jörg Fuchs; Helene Martelli; Roshni Dasgupta; Jonathan C Routh; Douglas S Hawkins; Ewa Koscielniak; Gianni Bisogno; David A Rodeberg
Journal:  Pediatr Blood Cancer       Date:  2021-02-01       Impact factor: 3.838

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.